Coronavirus Live Count Map India
remove_red_eye 1151 Views
COVID-19 Vaccine Updates
#Business And Medicine #Emergency Medicine #Hospital Medicine #Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
Hydroxychloroquine (HCQ) does not seem to reduce the risk for infection in people exposed to patients with confirmed COVID-19, revealed a randomized, double-blind, placebo-controlled prevention trial.
Investigators enrolled 821 asymptomatic participants from multiple sites in the United States and Canada. The incidence of new illness compatible with COVID-19 was not significantly different between those who received HCQ (49 of 414; 11.8%) and those who received placebo (58 of 407; 14.3); the absolute difference was −2.4 percentage points (95% confidence interval, −7.0 to 2.2; P = .35). The findings were published in the New England Journal of Medicine.